Loading
A phase 2 trial of Belzutifan in pheochromocytoma and paraganglioma, run by Merck Sharp & Dohme LLC, now recruiting.
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) is a phase 2 interventional study registered as NCT04924075 by Merck Sharp & Dohme LLC, with 355 participants planned, started 2021-08-12 and due to reach its primary completion in 2029-12-27. Interventions recorded: Belzutifan. Conditions listed: Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor. No results are recorded here; the registry entry is the source.
Shares Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127), Metastatic pheochromocytoma and paraganglioma.
Shares Belzutifan, Merck & Co. (MSD), Small-molecule kinase inhibitors.
Shares Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127), Metastatic pheochromocytoma and paraganglioma, Pheochromocytoma and paraganglioma (PPGL).
Shares Metastatic pheochromocytoma and paraganglioma, Pheochromocytoma and paraganglioma (PPGL).
Shares Belzutifan, Merck & Co. (MSD), Small-molecule kinase inhibitors.
Shares Metastatic pheochromocytoma and paraganglioma, Pheochromocytoma and paraganglioma (PPGL), Small-molecule kinase inhibitors.
Shares Belzutifan, Merck & Co. (MSD), Small-molecule kinase inhibitors.
Shares Belzutifan, Merck & Co. (MSD), Small-molecule kinase inhibitors.